Insta
J&J Covid-19 vaccine
United States-based pharma giant Johnson and Johnson (J&J) has sought approval for clinical trial of its single-shot Covid-19 vaccine on adolescents aged 12-17 years in India.
The single-shot Covid vaccine developed by Johnson and Johnson has shown 85 per cent efficacy in preventing severe Covid-19 disease in phase 3 clinical trials.
"Johnson & Johnson is committed to facilitating global equitable access to its COVID-19 vaccine and recognize the unmet needs of children. On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 – 17 years," Johnson & Johnson India spokesperson was quoted in a Economic Times report as saying.
Earlier this month, the single shot vaccine of J&J became the second COVID-19 vaccine which has been granted Emergency Use Authorisation (EUA) through the fast-track approval route by the Drug Controller General of India.
J&J has partnered with Indian vaccine maker Biological E Ltd for supply and manufacturing of its Covid-19 vaccine shot in the country.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest